ARK Genomic Revolution ETF – AMEX:ARKG

Add to watchlist

$24.18

-0.25

-1.02%

Market closed

Open in about 15 hours

-3.59%

month

-3.59%

quarter

-27.46%

year

Market Cap	1.25B
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	N/A

Revenue	N/A
EBITDA	N/A
Income	N/A
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

ARK Genomic Revolution ETF
Latest News

Tuesday, 3 December 2024
09:01	Best-Performing ETF Areas of Last Week	zacks.com
Tuesday, 8 October 2024
08:00	Interest Rate Regimes And ARKG: Underperformance Explained	seekingalpha.com
Tuesday, 27 August 2024
04:52	Almost Every Ark Fund Is Now Underperforming The Overall Market. Here's Why.	fool.com
Tuesday, 20 August 2024
11:01	5 Technology ETFs at the Forefront of the August Rebound	zacks.com
Thursday, 1 August 2024
12:00	5 Sector ETFs That Outperformed With Double-Digit Gains in July	zacks.com
Monday, 29 July 2024
09:01	Best ETFs of Last Week	zacks.com
Monday, 24 June 2024
01:07	ARKG: A Genomics Play But Active Isn't Adding Value	seekingalpha.com
Friday, 14 June 2024
08:00	BMO Transfers 3 BMO Mutual Fund ETF Series, Managed by ARK Investment Management, to Cboe Canada	businesswire.com
Thursday, 2 May 2024
16:28	Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April	marketwatch.com
Monday, 22 April 2024
05:43	3 Cathie Wood ETFs Just Hit 4-Month Lows. Are They Worth Buying Now?	The Motley Fool
Thursday, 4 April 2024
08:01	Time to Tap Healthcare ETFs on Nvidia's AI Ambition?	Zacks Investment Research
Monday, 25 March 2024
05:22	ARKG: Massive Potential, But Not Worth The Risk Yet For These 3 Reasons	Seeking Alpha
04:50	Cathie Wood Is Selling This High-Yield Dividend Stock. Should You?	The Motley Fool
Tuesday, 19 March 2024
14:45	3 Biotech ETFs Overdue for a Bounce	InvestorPlace
Wednesday, 27 December 2023
09:01	5 Best ETF Areas of Last Week	Zacks Investment Research
Monday, 18 December 2023
11:50	VIDEO: ETF of the Week: ARK Genomic Revolution ETF (ARKG)	ETF Trends
Thursday, 14 December 2023
14:17	Sector ETFs to Gain as Fed Stays Put, Sees Deeper Rate Cuts in 2024	Zacks Investment Research
14:04	ETF of the Week: ARK Genomic Revolution ETF (ARKG)	ETF Trends
Thursday, 30 November 2023
07:45	1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years	The Motley Fool
Wednesday, 22 November 2023
23:31	Analyzing ARKG's Trading Activity In Q3	Seeking Alpha
Monday, 20 November 2023
17:43	The 3 Best Gene Editing Stocks on the Frontier of Medicine	InvestorPlace
09:01	Best-Performing ETFs of Last Week	Zacks Investment Research
Friday, 17 November 2023
16:04	VettaFi Voices On: Accessing Disruptive Innovation	ETF Trends
Monday, 30 October 2023
15:02	5 ETF Areas That Spooked Investors in October	Zacks Investment Research
Monday, 16 October 2023
05:50	Why Wall Street Thinks This Artificial Intelligence (AI) Stock Could Skyrocket 140% Over the Next 12 Months	The Motley Fool
Thursday, 21 September 2023
16:22	Uranium prices are still ‘nowhere near the peak of the last cycle': Here's why nuclear energy ETFs could power your portfolio	Market Watch
Thursday, 24 August 2023
15:53	Best Healthcare ETFs to Buy Now	Kiplinger
Monday, 14 August 2023
08:45	3 Top Growth ETFs to Buy Right Now	The Motley Fool
Thursday, 27 July 2023
14:00	Cathie Wood Is Buying Up Shares of This Beaten-Down Biotech. Should You?	The Motley Fool
Monday, 17 July 2023
16:57	Cathie Wood Says ARK Funds Are Seeing Flows Coming Back	Bloomberg Markets and Finance

Ideas & Opinions

Seeking Alpha 14 Jan 2024

Week In Review: China Biopharmas Book $9B In Deals During JP Morgan Conference Week
Seeking Alpha 12 Jan 2024

Horiba: Wonderful Japanese Company At A Very Attractive Price
Seeking Alpha 7 Jan 2024

Week In Review: 2024 Kicks Off With 3 Deals Worth A Total Of $4B
Seeking Alpha 23 Jul 2023

Week In Review: Novartis In $1 Billion Deal For DTx Pharma
Seeking Alpha 1 Mar 2023

Invitae Investors Face More Dilution
Seeking Alpha 12 Jan 2023

Prime Medicine 'Crispr 3.0' Vs. Crispr Therapeutics
Seeking Alpha 18 Oct 2022

Bionano Genomics: Little Clinical Utility And A Whole Lot Of Burn
Seeking Alpha 11 Oct 2022

Teladoc: Cathie Wood Does It Again
Seeking Alpha 20 Sep 2022

Verve Therapeutics: Cathie Wood Adds To ARKK
Seeking Alpha 24 Aug 2022

CytoDyn: It Only Takes One Hit

Frequently Asked Questions (FAQ)

What's the price of ARK Genomic Revolution ETF stock today?

One share of ARK Genomic Revolution ETF stock can currently be purchased for approximately $24.18.
When is ARK Genomic Revolution ETF's next earnings date?

Unfortunately, ARK Genomic Revolution ETF's (ARKG) next earnings date is currently unknown.
Does ARK Genomic Revolution ETF pay dividends?

Yes, ARK Genomic Revolution ETF pays dividends and its trailing 12-month yield is 1.27% with 0% payout ratio. The last ARK Genomic Revolution ETF stock dividend of $0.79 was paid on 25 Sep 2025.
How much money does ARK Genomic Revolution ETF make?

ARK Genomic Revolution ETF has a market capitalization of 1.25B.
What is ARK Genomic Revolution ETF's stock symbol?

ARK Genomic Revolution ETF is traded on the AMEX under the ticker symbol "ARKG".
What is ARK Genomic Revolution ETF's primary industry?

Company operates in the Financial Services sector and Asset Management industry.
How do i buy shares of ARK Genomic Revolution ETF?

Shares of ARK Genomic Revolution ETF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
When ARK Genomic Revolution ETF went public?

ARK Genomic Revolution ETF is publicly traded company for more then 10 years since IPO on 31 Oct 2014.

ARK Genomic Revolution ETF

Exchange:

AMEX

Full time employees:

Industry:

Asset Management

Sector:

Financial Services

The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.

CIK: 0001579982
ISIN: US00214Q3020
CUSIP: 00214Q302